Bleomycin
- IVBleomycinCytotoxicity is cell cycle-specific to G2 phase
Mechanism of Action
- Binds to DNA, resulting in prevention of RNA transcription and protein synthesis.
Pharmacology
- Bone marrow-sparing, therefore often used when other antineoplastics are contraindicated.
Clinical Use
Indications
- Certain solid organ and haematologic organ malignancies, as guided by cancer specialists and local guidelines.
- Adverse Effects
- Nausea / vomiting / diarrhoea / anorexia
- Pneumonitis
- Alopecia
- Soft tissue damage (if extravasation)
Monitoring
- Lung function.